Xue‐Ning Yang

6.6k total citations · 1 hit paper
121 papers, 2.8k citations indexed

About

Xue‐Ning Yang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Xue‐Ning Yang has authored 121 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Pulmonary and Respiratory Medicine, 49 papers in Oncology and 22 papers in Cancer Research. Recurrent topics in Xue‐Ning Yang's work include Lung Cancer Treatments and Mutations (79 papers), Lung Cancer Diagnosis and Treatment (58 papers) and Lung Cancer Research Studies (26 papers). Xue‐Ning Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (79 papers), Lung Cancer Diagnosis and Treatment (58 papers) and Lung Cancer Research Studies (26 papers). Xue‐Ning Yang collaborates with scholars based in China, United States and India. Xue‐Ning Yang's co-authors include Yi‐Long Wu, Wen‐Zhao Zhong, Qing Zhou, Jin‐Ji Yang, Xu‐Chao Zhang, Hong‐Hong Yan, Jian Su, Hai‐Yan Tu, Zhi Xie and Hua‐Jun Chen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Xue‐Ning Yang

112 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

2016 741 citations Zhong‐Yi Dong, Wen‐Zhao Zhong et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Xue‐Ning Yang

Since Specialization

Citations

This map shows the geographic impact of Xue‐Ning Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xue‐Ning Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xue‐Ning Yang more than expected).

Fields of papers citing papers by Xue‐Ning Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xue‐Ning Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xue‐Ning Yang. The network helps show where Xue‐Ning Yang may publish in the future.

Co-authorship network of co-authors of Xue‐Ning Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Xue‐Ning Yang. A scholar is included among the top collaborators of Xue‐Ning Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xue‐Ning Yang. Xue‐Ning Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genomic profiling of aggressive pathologic features in lung adenocarcinoma 2025 ·Lung Cancer ·(unknown), Hongji Li, (unknown), (unknown), (unknown), Xue‐Ning Yang, Yi‐Long Wu, (unknown)	0
2	The Efficacy of the New Energy Vehicle Mandate Policy on Passenger Vehicle Market in China 2025 ·World Electric Vehicle Journal ·Ning Wang, Xiufeng Li, Xue‐Ning Yang	1
3	Rainfall and maximum temperature are dominant climatic factors influencing APSIM-Maize cultivar parameters sensitivity in semiarid regions 2024 ·European Journal of Agronomy ·Xue‐Ning Yang, Xuanze Zhang, Zhigan Zhao, Ning Ma, Jing Tian, Zhenwu Xu, Junmei Zhang, Yongqiang Zhang	2
4	Strong Agricultural Resilience to 2022 Southern China Drought 2024 ·Earth s Future ·(unknown), Yongqiang Zhang, Jing Tian, (unknown), (unknown), Xue‐Ning Yang, Xuanze Zhang, Ning Ma	5
5	Self-assembled Abietic acid encapsulated nanoparticles to improve the stability of Proanthocyanin B2 2024 ·Food Chemistry ·Ying Han, Xue‐Ning Yang, Shiyao Fu, Xiaoting Wang, Hua Zhang, Xiaojie Wei, Bin Li, Xin Yang	2
6	Recent nanotechnology improvements in Curcumin bioavailability and related applications 2024 ·Food Bioscience ·Ying Han, Shiyao Fu, Xue‐Ning Yang, Xiaoting Wang, Haitian Zhao, Xin Yang	10
7	Understanding the Propagation of Meteorological Drought to Groundwater Drought: A Case Study of the North China Plain 2024 ·Water ·Yuyin Chen, Yongqiang Zhang, Jing Tian, (unknown), Longhao Wang, Xue‐Ning Yang	12
8	Relationship of vegetarianism with body weight loss and ASCVD 2024 ·Frontiers in Nutrition ·(unknown), Xue‐Ning Yang, Lina Yao, Yan-Ping Liu, Panpan Hao	0
9	Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial 2022 ·Cancer Immunology Immunotherapy ·Cunte Chen, Si‐Yang Maggie Liu, Yedan Chen, Qiuxiang Ou, Hua Bao, Ling Xu, Yikai Zhang, Jia‐Tao Zhang, (unknown), Qing Zhou, Xue‐Ning Yang, Yang Shao, Yi‐Long Wu, Si‐Yang Liu, Yangqiu Li	1
10	Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments 2021 ·European Journal of Cancer ·Mei-Mei Zheng, Hai‐Yan Tu, Jin‐Ji Yang, Xu‐Chao Zhang, Qing Zhou, Chong‐Rui Xu, Ben‐Yuan Jiang, Xue‐Ning Yang, Xiaorong Yang, Jia‐Yi Deng, (unknown), Bing-Fei Xu, Xiu‐Mei Chen, Yang-Si Li, Yi‐Long Wu	19
11	High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer 2021 ·Thoracic Cancer ·(unknown), Yu Chen, Zhi Xie, Jie Jiang, (unknown), Wei‐Bang Guo, Wenqing Yan, Zhiyi Lv, (unknown), (unknown), Fangping Xu, Jin‐Ji Yang, Xue‐Ning Yang, Qing Zhou, (unknown), Zhou Zhang, Shaokun Chuai, Henghui Zhang, Yi‐Long Wu, Xu‐Chao Zhang	9
12	Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades 2019 ·SHILAP Revista de lepidopterología ·(unknown), Xue‐Ning Yang, Yongsheng Huang, Meng Zhao, Min Li, Ke Ma, (unknown), Cheng Zhan, Qi Wang	31
13	Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma 2019 ·Thoracic Cancer ·Kai Yin, (unknown), (unknown), Yu Chen, Zhi Xie, Zhiyi Lv, Wei‐Bang Guo, (unknown), Xue‐Ning Yang, Wenqing Yan, Yi‐Long Wu, Xu‐Chao Zhang	12
14	P1.01-28 Mutational Heterogeneity Between Primary Pulmonary Cancer Lesions and Matched Brain Metastases 2019 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), Dong Zhou, Xiaoyi Lin, Kai Yin, Hua Feng, Weijian Guo, (unknown), (unknown), (unknown), Lu Dai, Xue‐Ning Yang, (unknown), (unknown)	1
15	Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC 2019 ·Journal of Thoracic Oncology ·Mei-Mei Zheng, Yang-Si Li, Ben‐Yuan Jiang, Hai‐Yan Tu, Wen‐Fang Tang, Jin‐Ji Yang, Xuchao Zhang, Junyi Ye, Hong‐Hong Yan, Jian Su, Qing Zhou, Wen‐Zhao Zhong, Xue‐Ning Yang, Wei‐Bang Guo, Shannon Chuai, Zhou Zhang, Hua‐Jun Chen, Zhen Wang, Chao Liu, Yi‐Long Wu	75
16	Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer 2018 ·Thoracic Cancer ·Jin‐Hyoung Kang, Hua‐Jun Chen, Xu‐Chao Zhang, Jian Su, Qing Zhou, Hai‐Yan Tu, Zhen Wang, (unknown), Wen‐Zhao Zhong, Xue‐Ning Yang, Zhihong Chen, Yan Ding, Xue Wu, Mei Wang, Jiangang Fu, Zhenfan Yang, Xian Zhang, Yang Shao, Yi‐Long Wu, Jin‐Ji Yang	17
17	Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement 2018 ·Journal of Thoracic Oncology ·Chao Zhang, Shaolei Li, Qiang Nie, Song Dong, (unknown), Xue‐Ning Yang, Yi‐Long Wu, Yue Yang, Wen‐Zhao Zhong	66
18	P1.05-046 Randomized Study of Adjuvant Docetaxel vs. Observation for Completely Resected Stage IB-IIIa NSCLC with 11 Years' Median Follow-Up 2017 ·Journal of Thoracic Oncology ·Wen‐Zhao Zhong, Xue‐Ning Yang, Hong‐Hong Yan, Ri-Qiang Liao, Qiang Nie, Song Dong, Ben‐Yuan Jiang, Qing Zhou, Jin‐Ji Yang, Yi‐Long Wu	1
19	Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study 2017 ·World Journal of Surgical Oncology ·Song Dong, Ning Zhao, Wei Deng, Huiwen Sun, Feiyu Niu, Jin‐Ji Yang, Wen‐Zhao Zhong, Feng Li, Hong‐Hong Yan, Chong‐Rui Xu, Qiuyi Zhang, Xue‐Ning Yang, Ri-Qiang Liao, Qiang Nie, Yi‐Long Wu	2
20	Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma breakdown → 2016 ·Clinical Cancer Research ·Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang, Jian Su, Zhi Xie, Si‐Yang Maggie Liu, Hai‐Yan Tu, Hua‐Jun Chen, Yue‐Li Sun, Qing Zhou, Jin‐Ji Yang, Xue‐Ning Yang, Jiaxin Lin, Hong‐Hong Yan, Hao-Ran Zhai, Li‐Xu Yan, Ri-Qiang Liao, Si-Pei Wu, Yi‐Long Wu	741

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact